An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis C
An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis C
This study is a two-way, non-interventional long-term dynamic follow-up clinical
 observational cohort study. In the Second Division of Liver Diseases, Beijing Ditan Hospital,
 Capital Medical University, chronic hepatitis C patients who were treated with interferon
 combined with ribavirin (PR) antiviral therapy (PR treatment for 6 months or more) and / or
 direct acting antivirals (DAAs ), and the baseline, antiviral treatment and discontinuation
 follow-up data of patients before antiviral treatment were collected, and follow-up
 observations of patients were carried out for every 3-6 months. The clinical data such as
 clinical biochemistry, HCV RNA and serological indicators (anti-HCV), AFP, and liver imaging
 (liver ultrasound) were collected during the study period. The virological response and
 clinical outcomes of chronic hepatitis C antiviral therapy were observed for at least 144
 weeks. The incidence of liver cancer and decompensated liver cirrhosis after discontinuation
 of the drug was the main evaluation index. The aim is to explore long-term virological
 response and clinical outcomes, and elucidate its influencing factors.
This study is a two-way, non-interventional long-term dynamic follow-up clinical
 observational cohort study. Enrolled in the Second Division of Liver Diseases, Beijing Ditan
 Hospital, Capital Medical University, via interferon combined with ribavirin (PR) antiviral
 therapy (PR treatment for 6 months or more) and / or direct acting antivirals (DAAs ) For
 patients with chronic hepatitis C treated, collect baseline, antiviral treatment and
 discontinuation follow-up data of patients before antiviral treatment, and follow-up
 observations of patients enrolled every 3-6 months. Collect clinical data such as clinical
 biochemistry, HCV RNA and serological indicators (anti-HCV), AFP, and liver imaging (liver
 ultrasound) during the study period. The virological response and clinical outcomes of
 chronic hepatitis C antiviral therapy were observed for at least 144 weeks. The incidence of
 liver cancer and decompensated liver cirrhosis after discontinuation of the drug was the main
 evaluation index. The aim is to explore long-term virological response and clinical outcomes,
 and elucidate its influencing factors.
Inclusion Criteria:

 -  Ages 18 to 75;

 -  Unlimited gender;

 -  Patients with chronic hepatitis C treated with interferon combined with ribavirin (PR)
 antiviral therapy (PR therapy for 6 months or more) and / or direct antiviral drugs
 (DAAs). All patients with chronic hepatitis C met the diagnostic criteria of the
 Chinese Guidelines for the Prevention and Treatment of Chronic Hepatitis C (2015)

 -  No hormones and / or immunosuppressants and other hepatoprotective drugs;

 -  Sign a written informed consent.

 Exclusion Criteria:

 -  Combined with other hepatitis virus (HBV, HDV) infections;

 -  Immune liver disease;

 -  HIV infection;

 -  long-term alcohol and / or other liver damage drugs;

 -  mental illness;

 -  Evidence of liver tumor (liver cancer or AFP> 100 ng / ml);

 -  Decompensated cirrhosis;

 -  Those who have serious heart, brain, lung, kidney and other system diseases that
 cannot participate in long-term follow-up;

 -  There are hormones and / or immunosuppressants and other hepatoprotective drugs.